| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1R |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H10028N1728O2020S42 |
| Molar mass | 145712.01 g·mol−1 |
  (what is this?) (verify) | |
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1][2]
Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[3][4]
YouTube Encyclopedic
-
1/5Views:3954913 6371 020316
-
Laura van t’Veer, UC San Francisco - Stanford Medicine Big Data | Precision Health 2016
-
Sarcoma de Ewing
-
Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of Benefit
-
Keynote Lecture 6: Statistics for clinicians
-
Targeting the C-MET Receptor as a Therapeutic Strategy - Dr. Johanna Bendell and Dr. David Spige
Transcription
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
- ^ Martínez P, Sales Fidalgo PA, Felip E (October 2014). "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs. 23 (10): 1423–32. doi:10.1517/13543784.2014.951434. PMID 25189625. S2CID 7318164.
- ^ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
- ^ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 19 May 2023, at 15:27